PREVAIL THERAPEUTICS
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for Parkinson’s with GBA, REGENXBIO, and OrbiMed, and is headquartered in New York, NY.
PREVAIL THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Health Diagnostics Therapeutics
Founded:
2017-01-01
Status:
Active
Contact:
917-336-9310
Email Addresses:
[email protected]
Total Funding:
129 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Content Delivery Network Font Awesome
Similar Organizations
Affinia Therapeutics
Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.
Aopia Biosciences
Aopia Biosciences is a biotechnology business focused on developing cutting-edge bioengineering solutions and technologies.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Century Therapeutics
Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
E-Health Now LLC
We are the first HIPAA compliant platform that focuses on optimizing cancer treatment plans for patients in China locally, on a B2B model.
GPS Dental
GPS Dental is a Dental Service Organization that provides care to communities through philanthropic service.
Modis Therapeutics
Modis Therapeutics is bringing disease-modifying therapies to patients with rare genetic diseases.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
EcoR1 Capital
EcoR1 Capital investment in Series B - Prevail Therapeutics
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - Prevail Therapeutics
Adage Capital Management
Adage Capital Management investment in Series B - Prevail Therapeutics
OrbiMed
OrbiMed investment in Series B - Prevail Therapeutics
RA Capital Management
RA Capital Management investment in Series B - Prevail Therapeutics
Biotechnology Value Fund
Biotechnology Value Fund investment in Series B - Prevail Therapeutics
Pontifax
Pontifax investment in Series B - Prevail Therapeutics
Omega Funds
Omega Funds investment in Series B - Prevail Therapeutics
Surveyor Capital
Surveyor Capital investment in Series B - Prevail Therapeutics
AbbVie Biotech Ventures
AbbVie Biotech Ventures investment in Series B - Prevail Therapeutics
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2023-05-17 | Scribe Therapeutics | Prevail Therapeutics investment in Convertible Note - Scribe Therapeutics | N/A |
More informations about "Prevail Therapeutics"
About Us - Prevail Therapeutics
Prevail was founded in a collaborative effort by Asa Abeliovich, M.D., Ph.D., OrbiMed and The Silverstein Foundation for Parkinson’s with GBA, who shared a common vision: to eradicate Parkinson’s disease and related disorders. We …See details»
Our Science - Prevail
Gaucher Disease. Gaucher disease is a rare genetic disorder driven by mutations in the GBA1 gene, that like PD-GBA, can cause lysosomal dysfunction and have a wide range of effects on …See details»
Lilly Completes Acquisition of Prevail Therapeutics
INDIANAPOLIS, Jan. 22, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: …See details»
Prevail Therapeutics | Gaucher Community Alliance
Prevail Therapeutics is leading a new era of gene therapy-based treatments with the potential to slow or stop the progression of neurodegenerative diseases, including Gaucher disease and genetic forms of Parkinson’s disease. …See details»
Prevail Therapeutics Inc. - AnnualReports.com
Prevail is a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients …See details»
Prevail Therapeutics - Crunchbase Investor Profile
Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease and other neurodegenerative diseases. Prevail was launched in 2017 by The Silverstein Foundation for …See details»
Our Programs - Pipeline - Prevail
PR001. PR001 is being developed as a potentially disease-modifying, single-dose gene therapy for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and Gaucher disease Types 1 (GD1). PD-GBA and Gaucher disease …See details»
Eli Lilly acquires Prevail Therapeutics - 2020-12-15 - Crunchbase
Dec 15, 2020 Prevail Therapeutics Prevail Therapeutics is a biotechnology company focused on developing novel gene therapies for patients with Parkinson’s disease. Acquiring Organization: …See details»
With Prevail Acquisition, Lilly Plans New Gene Therapy …
Dec 21, 2020 Ñ>D ô! æþß7ÕþÛþùº¦O$2 HÔJUi6§ â„¢,~±Ó¾9¶G $.)Ä$À –ªúÿ÷«Ò/ ä › » v@Å Ð%«î}ú%ªa «j©Ià9iËœûîÆ’ÿ Å¡ ªkˆš†±z ...See details»
Prevail Therapeutics - Overview, News & Similar companies
Apr 23, 2024 Who is Prevail Therapeutics. To prove more powerful than opposing forces. To be victorious. To gain ascendance through strength. To triumph. We are developing disease …See details»
Prevail Therapeutics Company Profile 2024: Valuation, Investors ...
Prevail Therapeutics’s most recent deal was a Later Stage VC with Scribe Therapeutics. The deal was made on 16-May-2023. The deal was made on 16-May-2023. Company NameSee details»
Patients and Families - Prevail
Enrolling in Prevail’s clinical trials is the primary way that patients and caregivers who seek access to Prevail’s investigational drug(s) may receive those drug(s). Information about …See details»
Lilly acquires biotechnology company Prevail Therapeutics for …
Mar 24, 2022 Lilly concluded the acquisition through the merger of Tyto Acquisition with and into Prevail, with Prevail becoming Lilly’s wholly owned subsidiary. Cell & Gene Therapy Coverage …See details»
Scribe Announces Collaboration with Prevail, a Wholly Owned …
May 16, 2023 Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced a strategic collaboration with Prevail …See details»
Lilly Completes Acquisition of Prevail Therapeutics
Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery and development at Lilly, extending Lilly's research efforts through the creation of a …See details»
Prevail Therapeutics - Investments, Portfolio & Company Exits
May 17, 2023 Which industries has this organization most actively invested in? Show . Announced Date . Organization Name . Lead Investor ... Number of Diversity Investments 1. …See details»
Lilly Announces Agreement to Acquire Prevail Therapeutics
Dec 15, 2020 INDIANAPOLIS and NEW YORK, Dec. 15, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a …See details»
Lilly Announces Agreement to Acquire Prevail Therapeutics | Eli …
INDIANAPOLIS and NEW YORK, Dec. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement …See details»
Our Progress - News - Prevail
Prevail Therapeutics features on Behind the Mystery, a recurring series on The Balancing Act devoted to advocating for rare and genetic diseases. The episode, “Behind the Mystery of …See details»
Prevail Therapeutics - Funding, Financials, Valuation & Investors
Prevail Therapeutics is registered under the ticker NASDAQ:PRVL . Their stock opened with $17.00 in its Jun 20, 2019 IPO. Stock Symbol NASDAQ:PRVL ; Valuation at IPO $578M; …See details»